Auto Amazon Links: No products found. Blocked by captcha.
A revolutionary cancer drug has been introduced in Wales that has the potential to significantly extend the survival time of individuals with incurable breast cancer. Capivasertib, a drug shown to double the life expectancy of half of women with estrogen-fueled breast cancer when used in combination with hormone therapy, is now available to patients through the NHS. This development offers hope to individuals like Gwen Buchan, a 62-year-old with terminal breast cancer, who expressed her gratitude for the opportunity to witness her son’s wedding thanks to this groundbreaking medication.
Breast cancer is the most prevalent form of cancer in the UK, affecting one in seven women during their lifetime, with 75% of patients surviving for 10 years or more post-diagnosis. Research conducted by experts at Velindre Cancer Centre and Cardiff University led to the development of Capivasertib, now accessible to breast cancer patients in Wales as of April. Furthermore, studies have shown that this drug has the potential to reduce the progression rate of cancer by more than half, offering a glimmer of hope to those battling the disease.
Despite its previous approval by the US Food and Drug Administration in 2023, Capivasertib is only now becoming available to patients in England and Wales this year through the NHS. Dr. Simon Waters, a consultant medical oncologist at Velindre Cancer Centre, has hailed this milestone as a significant achievement in improving treatment options for patients. The drug’s ability to target specific gene mutations prevalent in a substantial portion of individuals with hormone receptor positive secondary breast cancer makes it a promising new addition to the standard treatment repertoire.
Capivasertib works by neutralizing a specific protein that drives resistance to hormone therapy when combined with capivasertib, as evidenced in clinical trials. Patients who have received this combination therapy have shown a remarkable increase in overall survival time, with some experiencing a doubling of lifespan. Dr. Nicola Williams, national director of support and delivery at Health and Care Research Wales, emphasized the profound impact that this drug could have on patients’ quality of life and lifespan, providing hope and extended time to cherish with loved ones for those battling incurable breast cancer
Read the full article from The BBC here: Read More
Auto Amazon Links: No products found. Blocked by captcha.